Glaukos Corporation · NYSE:GKOS
Glaukos — Q1 2023 Earnings Presentation
10 slides from Glaukos's earnings presentation, May 3, 2023
Slide 1: Glaukos: Innovation is at the core of everything we do
GLAUKOS Innovation is at the core of everything we do. At Glaukos, we push the limits of science and technology to solve unmet needs in chronic eye diseases.
Slide 2: Franchise Revenue Performance
Franchise Revenue Performance
Slide 3: 1Q 2023 Revenue Mix
1Q 2023 Revenue Mix Corneal Health $17.7M U.S. Glaucoma $35.1M International Glaucoma $21.1M
Slide 4: Glaukos Pipeline Summary
Glaukos Pipeline Summary Market Platform Product Indication U.S. Status e iPM Delivery of vsneasti during ophthalmic sugery FDA Clearance Received iaocess Manual cutting of TM during ophthalmic surgery FDA Clearance Received Mild-to-maderate primary open-angle glaucoma in Sant iStent /istent inject
Slide 5: Peer-reviewed study on long-term endothelial safety of iStent inject
Another recent clinical highlight is a peer-reviewed study published in the American Journal of Ophthalmology authored by Dr. Ike K. Ahmed titled “Long-Term Endothelial Safety Profiles with iStent inject in Patients with Open-Angle Glaucoma.” This study examined 5-year postoperative safety data of
Slide 6: Additional Information
Additional Information
Slide 7: Condensed Consolidated Statements of Operations
GLAUKOS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS. (unaudited) (in thousands, except per share amounts) Net sales Cost of sales Gross profit Operating expenses: Selling, general and administrative Research and development Litigation-related settlement Total operating expenses (Loss
Slide 8: Condensed Consolidated Balance Sheets
GLAUKOS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS. (in thousands, except par values) Assets Current assets: Cash and cash equivalents Short-term investments Accounts receivable, net Inventory Prepaid expenses and other current assets Total current assets Restricted cash Property and equipmen
Slide 9: GAAP to Non-GAAP Reconciliations
GLAUKOS CORPORATION GAAP to Non-GAAP Reconciliations (in thousands, except per share amounts and percentage data) (unaudited) Q1 2023 Qi 2022 GAAP Adjustments Non-GAAP GAAP. Adjustments Non-GAAP Cost of sales $ 18,071 $ (5,523) (a) S 12,548 S 17,063 S$ (5,551) (a) $_‘11,512 Gross Margin 75.5% 7.5% 8
Slide 10: Non-GAAP disclosures for past quarterly results
For Non-GAAP disclosures associated with the company’s past quarterly results, please see reconciliations here.